REGN - Spark Newswire

2 minute read

News

Regeneron Announced Evkeeza Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol; Trial Met Primary Endpoint

Today, 3:33 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH).

REGN

1 minute read

FDA Approves Regeneron and Sanofi’s Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

By Ragothaman Srinivasan

Today, 3:33 AM

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

REGN

4 minute read

Regeneron, Sanofi Report FDA Approved Dupixent As Treatment For Adults, Children Aged 12+ With Esophagitis

By Benzinga Newsdesk

Today, 3:33 AM

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly

REGN

4 minute read

Options

9 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights

Today, 3:33 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

2 minute read

Earnings

Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed

By Benzinga Insights

Today, 3:33 AM

Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between quarters.

REGN

1 minute read

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

By Vandana Singh

Today, 3:33 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased…

REGN

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 3:33 AM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

2 minute read

Analyst Ratings

Where Regeneron Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 3:33 AM

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

REGN

1 minute read

Here’s Why This Analyst Cut Price Target On Regeneron

By Vandana Singh

Today, 3:33 AM

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc’s price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks…

REGN

4 minute read

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More

By Shanthi Rexaline

Today, 3:33 AM

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.

ABBV

Feed Symbols: REGN